FEB 18, 2016 10:11 AM PST

Dramatic Remissions Seen in Immunotherapy Trial


 
Dr. Stanley RiddellDramatic remissions have been seen in a cancer immunotherapy trial for patients with blood cancers. Specifically, 27 out of 29 patients with advanced blood cancer sustained remissions with this treatment. The results are preliminary as the study is ongoing at the Fred Hutchinson Cancer Research Center in Seattle.

Immunotherapy is a revolutionary approach to fighting cancer. The treatment is still experimental, so it is generally reserved for those whose cancer was resistant to other cancer-fighting treatments. The trial began in 2013, and many of the recruited patients were not expected to survive for more than a few months.

The team at Fred Hutchinson uses an immunotherapy technique called adoptive T-cell therapy. The treatment works by first taking a patient’s T-cells, a type of white blood cell. T cells have the ability to detect and attack foreign or abnormal cells. Unfortunately, cancer can exhaust and overpower T cells. In addition, tumors use an array of techniques to evade them.

After taking the T cells, the researchers then genetically engineer them with synthetic molecules called chimeric antigen receptors (CAR). The CARs enable the T cells to attack the body’s cancer cells. The army of cancer-fighting cells is grown in a lab and then given back to the patient. The therapy does not need to be repeatedly administered because T cells can continue to multiply once delivered back into the patient.

The researchers noticed dramatic remissions in the treatment of patients with two types of cancers: lymphomas and some types of leukemias. However, while the treatment shows promising results, “much like chemotherapy and radiotherapy, it’s not going to be a save-all,” said Immunotherapy researcher and oncologist Stanley Riddell. Some patients may require alternative treatments.

Ridell and his colleagues are continuously revising the T-cell therapy protocols in hopes to make the therapy more effective and reduce the harmful side effects. The side effects, sometimes serious, have included fevers, drops in blood pressure, neurological symptoms, and cytokine release syndrome. Seven patients in the study ended up in intensive care due to the side effects. Two of the study participants died. The team found that administering the lowest dose of T cells to those with the highest tumor burdens lowered the risk of serious side effects.

The researchers are now working on developing safer and easier to design T cells. It is important to note that the research has not yet been published, and has thus not been evaluated by scientists independent of the study.

Riddell shared the trial results on Sunday at the American Association for the Advancement of Science in Washington D.C.

Sources: Fred Hutchinson Cancer Research Center: Hutch News, RT America video
About the Author
  • Julianne (@JuliChiaet) covers health and medicine for LabRoots. Her work has been published in The Daily Beast, Scientific American, and MailOnline. While primarily a science journalist, she has also covered culture and Japanese organized crime. She is the New York Board Representative for the Asian American Journalists Association (AAJA). • To read more of her writing, or to send her a message, go to Jchiaet.com
You May Also Like
AUG 19, 2019
Cancer
AUG 19, 2019
Don't Combine Breast and Gyno Surgery, Study Advises
Surgeries can be stressful and difficult for patients, and it’s understandable that some would want to reduce the number of days they need to devote...
AUG 19, 2019
Genetics & Genomics
AUG 19, 2019
Does Diet Shape Our Microbiome More than Genetics?
Recent findings from mouse studies have concluded that genetics may have a more important role than environmental factors in the composition of the microbi...
AUG 19, 2019
Earth & The Environment
AUG 19, 2019
Cutting air pollution saves lives in New York
New research published in Environmental Research Letters reports that lowering New York’s air pollution levels has had drastically positive results....
AUG 19, 2019
Cancer
AUG 19, 2019
Ladies, chicken or steak?
Ladies, trying to choose between chicken or steak? New research published in the International Journal of Cancer might help you decide. According to the st...
AUG 19, 2019
Cannabis Sciences
AUG 19, 2019
Will Cannabis Go Organic in California?
Organic foods are growing in popularity. Can cannabis farmers get in on the game? In the U.S., the organic market breached the $50 billion mark for the fir...
AUG 19, 2019
Plants & Animals
AUG 19, 2019
The Science Behind Why Pollen Makes You Sneeze
You’ve undoubtedly heard of something called ‘Hay Fever.’ This term effectively describes the allergy-like symptoms that many people get...
Loading Comments...